EV

Evoke Pharma IncNASDAQ EVOK Stock Report

Last reporting period 30 Jun, 2024

Updated 26 Nov, 2024

Last price

Market cap $B

0.004

Micro

Exchange

XNAS - Nasdaq

EVOK Stock Analysis

EV

Uncovered

Evoke Pharma Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-44/100

Low score

Market cap $B

0.004

Dividend yield

Shares outstanding

3.343 B

Evoke Pharma, Inc. (Evoke) is a specialty pharmaceutical company that owns and operates in the development and commercialization of pharmaceutical products. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. Evoke is developing its product Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Gimoti, is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a formulation of metoclopramide offering systemic delivery by nasal spray administration.

View Section: Eyestock Rating